Customized phage therapies to eradicate
harmful bacteria in chronic diseases
BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference
Ness Ziona, Israel – February 17, 2020 – BiomX, a microbiome company developing both natural and engineered phage therapies, today announced that the company will present pre-clinical data from its colorectal cancer program at the plenary session of the...
- Tel Aviv Stock Exchange trading effective February 6th, 2020 - BiomX common shares will continue to trade on the NYSE under the symbol PHGE Ness Ziona, Israel – February 3rd , 2020 – BiomX Inc. (NYSE: PHGE), a clinical-stage biotechnology company...
BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin
- Primary endpoints are safety and tolerability - Exploratory endpoints include proof of principle by measurement of C. acnes skin levels - Clinical data are expected at the end of the first quarter of 2020 Ness Ziona, Israel – Dec. 2, 2019 – BiomX Inc. (NYSE: PHGE),...